A global phase 2 trial found that giving durvalumab plus chemotherapy before surgery enabled most patients with resectable or borderline resectable non-small-cell lung cancer to have an operation, with encouraging pathological complete response rates and no new safety concerns.
Another “encouraging” phase 2 with a fancy name. Ping me when it reads out at phase 3.